Kelly M. Brunk, Senior Manager of Clinical Initiatives at NCODA, posted the following on LinkedIn:
“Excited to share our latest case report, co-authored with my colleagues from the University of Kansas Cancer Center!
We followed the journey of a 58-year-old man with HIV and a CD4 count of 53 cells/mm³, diagnosed with stage 4 left frontotemporal squamous cell carcinoma. After his cancer recurred following initial treatments, he started pembrolizumab therapy.
Incredible results: A complete response was observed just 83 days in, lasting for a year, even with low CD4 counts. This case highlights that immunotherapy can be both safe and effective for solid organ malignancies in HIV-positive patients.
We hope our findings inspire further research in this area.”